The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an McL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination
Blood - United States
doi 10.1182/blood-2018-99-119793
Full Text
Open PDFAbstract
Available in full text
Date
November 29, 2018
Authors
Publisher
American Society of Hematology